Corporate Report

Overview

The report presents Fuji Pharma's Long-term Vision for 2035 alongside a new Mid-Term Business Plan focused on women's healthcare, biosimilars, and global CMO growth. The company reports 1,658 consolidated employees and identifies materiality topics spanning environmental considerations, talent development, human rights, and governance. It also describes TCFD-based climate disclosure and SBTi-approved targets, including a 42% reduction in Scope 1 and 2 emissions by 2030 from 2022.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 October 2023 – 30 September 2024
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services